mRNA Delivery System for Targeting Antigen‐Presenting Cells In Vivo
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The encapsulation of mRNA in nanosystems as gene vaccines for immunotherapy purposes has experienced an exponential increase in recent years. Despite the many advantages envisaged within these approaches, their application in clinical treatments is still limited due to safety issues. These issues can be attributed, in part, to liver accumulation of most of the designed nanosystems and to the inability to transfect immune cells after an intravenous administration. In this context, this study takes advantage of the known versatile properties of the oligopeptide end‐modified poly (β‐amino esters) (OM‐PBAEs) to complex mRNA and form discrete nanoparticles. Importantly, it is demonstrated that the selection of the appropriate end‐oligopeptide modifications enables the specific targeting and major transfection of antigen‐presenting cells (APC) in vivo, after intravenous administration, thus enabling their use for immunotherapy strategies. Therefore, with this study, it can be confirmed that OM‐PBAE are appropriate systems for the design of mRNA‐based immunotherapy approaches aimed to in vivo transfect APCs and trigger immune responses to fight either tumors or infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Merad, M., Sathe, P., Helft, J., Miller, J., & Mortha, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074950 · Cited by 2,309
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Biodegradable synthetic polymers: Preparation, functionalization and biomedical application
Tian, H., Tang, Z., Zhuang, X., Chen, X., & Jing, X. (2012) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.06.004 · Cited by 1,293
Flow Cytometric Analysis of Macrophages and Dendritic Cell Subsets in the Mouse Lung
Misharin, A. V., Morales-Nebreda, L., Mutlu, G. M., Budinger, G. R. S., & Perlman, H. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0086ma · Cited by 838
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719
A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy
Cho, N.-H., Cheong, T.-C., Min, J. H., Wu, J. H., Lee, S. J., Kim, D., Yang, J.-S., Kim, S., Kim, Y. K., & Seong, S.-Y. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.149 · Cited by 514
Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.01.006 · Cited by 368
Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation
Su, X., Yu, Y., Zhong, Y., Giannopoulou, E. G., Hu, X., Liu, H., Cross, J. R., Rätsch, G., Rice, C. M., & Ivashkiv, L. B. (2015) · Nature Immunology · doi:10.1038/ni.3205 · Cited by 298
Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.202 · Cited by 248
Rajamathi, C. R., Gupta, U., Kumar, N., Yang, H., Sun, Y., Süβ, V., Shekhar, C., Schmidt, M., Yan, B., Parkin, S., et al. (2016) · arXiv · doi:10.48550/arxiv.1608.03783 · Cited by 3
Cited by
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
“Recently, end-capping the acrylate groups on PBAEs with CKKK oligopeptide via Michael addition afforded oligopeptidemodified PBAEs (OM-PBAEs) (Figure 2), which targeted antigenpresenting cells (APCs).(93) Such targeting strategies have their limitations and generally rely on high-throughput screening to find successfu…”
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
Advances in mRNA Vaccines for Infectious Diseases
Zhang, C., Maruggi, G., Shan, H., & Li, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00594 · Cited by 665
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Kim, J., Eygeris, Y., Gupta, M., & Sahay, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.014 · Cited by 514
Metadata
- Authors
- Fornaguera, C., Guerra‐Rebollo, M., Ángel Lázaro, M., Castells‐Sala, C., Meca‐Cortés, O., Ramos‐Pérez, V., Cascante, A., Rubio, N., Blanco, J., & Borrós, S.
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2018-06-19
- Volume
- 7
- Issue
- 17
- Pages
- e1800335-e1800335
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- OpenAlex
- W2809044246
- Cited by
- 94
- References
- 11
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.